Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8219214 | 0.96 | SMN1; SMN2 (0.52) | SMN1; SMN2BAZ2ACASP3CASP7CASP8 | |
| SCHEMBL12215949 | 0.96 | SMN1; SMN2 (0.52) | SMN1; SMN2BAZ2ACASP3CASP7CASP8 | |
| Bromide SCHEMBL29391160 | 0.95 | SMN1; SMN2 (0.51) | SMN1; SMN2BAZ2ACASP3CASP7CASP8 | |
| SCHEMBL1245930 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2CASP3CASP7CASP8RAB9A | |
| SCHEMBL996638 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2CASP3CASP7CASP8RAB9A | |
| SCHEMBL2142696 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2CASP3CASP7CASP8RAB9A | |
| SCHEMBL2142237 | 0.80 | RAB9A (0.57) | SMN1; SMN2CASP3CASP7CASP8RAB9A | |
| SCHEMBL16401499 | 0.80 | BAZ2A (0.46) | SMN1; SMN2BAZ2ACASP8ALDH1A1MEN1 | |
| SCHEMBL1228518 | 0.80 | BAZ2A (0.52) | SMN1; SMN2BAZ2ACASP3CASP7CASP8 | |
| Bromide SCHEMBL5061856 | 0.79 | BAZ2A (0.51) | SMN1; SMN2BAZ2ACASP3CASP7CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105579444-B | Piperidinylindole derivatives and their use as complement factor B inhibitors | 诺华股份有限公司 | 2018-05-01 | — | — | CN | disclosed |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| EP-3022192-B1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| CN-105579444-A | Piperidinylindole derivatives and their use as complement factor B inhibitors | NOVARTIS AG | 2016-05-11 | — | — | CN | disclosed |
| WO-2015009616-A1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, TFPI, TFPI2 | SMN1; SMN2 4416/4885BAZ2A 1933/4885CASP3 3164/4885 |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, C5, TFPI | SMN1; SMN2 4591/4885BAZ2A 1461/4885CASP3 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.